These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31331195)

  • 1. Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring.
    Trotta L; Kabeya Y; Buyse M; Doffagne E; Venet D; Desmet L; Burzykowski T; Tsuburaya A; Yoshida K; Miyashita Y; Morita S; Sakamoto J; Praveen P; Oba K
    Clin Trials; 2019 Oct; 16(5):512-522. PubMed ID: 31331195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional Trial Group Trial.
    Timmermans C; Doffagne E; Venet D; Desmet L; Legrand C; Burzykowski T; Buyse M
    Gastric Cancer; 2016 Jan; 19(1):24-30. PubMed ID: 26298185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A statistical approach to central monitoring of data quality in clinical trials.
    Venet D; Doffagne E; Burzykowski T; Beckers F; Tellier Y; Genevois-Marlin E; Becker U; Bee V; Wilson V; Legrand C; Buyse M
    Clin Trials; 2012 Dec; 9(6):705-13. PubMed ID: 22684241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central statistical monitoring: detecting fraud in clinical trials.
    Pogue JM; Devereaux PJ; Thorlund K; Yusuf S
    Clin Trials; 2013 Apr; 10(2):225-35. PubMed ID: 23283577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data-driven risk identification in phase III clinical trials using central statistical monitoring.
    Timmermans C; Venet D; Burzykowski T
    Int J Clin Oncol; 2016 Feb; 21(1):38-45. PubMed ID: 26233672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linear mixed-effects models for central statistical monitoring of multicenter clinical trials.
    Desmet L; Venet D; Doffagne E; Timmermans C; Burzykowski T; Legrand C; Buyse M
    Stat Med; 2014 Dec; 33(30):5265-79. PubMed ID: 25213096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A computationally simple central monitoring procedure, effectively applied to empirical trial data with known fraud.
    van den Bor RM; Vaessen PWJ; Oosterman BJ; Zuithoff NPA; Grobbee DE; Roes KCB
    J Clin Epidemiol; 2017 Jul; 87():59-69. PubMed ID: 28412468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Fraud in a Clinical Trial Using Unsupervised Statistical Monitoring.
    de Viron S; Trotta L; Schumacher H; Lomp HJ; Höppner S; Young S; Buyse M
    Ther Innov Regul Sci; 2022 Jan; 56(1):130-136. PubMed ID: 34590286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the performance of methods for central statistical monitoring of a binary or continuous outcome in multi-center trials: A simulation study.
    Ge L; Wang Z; Liu CC; Childress S; Wildfire J; Wu G
    Contemp Clin Trials; 2024 Aug; 143():107580. PubMed ID: 38796099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-based centralized data monitoring of clinical trials at the time of COVID-19 pandemic.
    Afroz MA; Schwarber G; Bhuiyan MAN
    Contemp Clin Trials; 2021 May; 104():106368. PubMed ID: 33775899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical challenges for central monitoring in clinical trials: a review.
    Oba K
    Int J Clin Oncol; 2016 Feb; 21(1):28-37. PubMed ID: 26499195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early stopping rules and long-term follow-up in phase III trials.
    Pignon JP; Arriagada R
    Lung Cancer; 1994 Mar; 10 Suppl 1():S151-9. PubMed ID: 8087505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detecting qualitative interactions in clinical trials with binary responses.
    Kitsche A
    Pharm Stat; 2014; 13(5):309-15. PubMed ID: 25049176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of a Rigorous Quality Program on 3D Echocardiography Data Quality in an International Multisite Randomized Trial.
    Crowley AL; Yow E; Rabineau D; Norris C; White J; Daubert MA; Velazquez EJ; Barnhart H; Krucoff MW; Rao SV; Douglas PS
    JACC Cardiovasc Imaging; 2018 Dec; 11(12):1918-1920. PubMed ID: 30121272
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials.
    Buyse M; George SL; Evans S; Geller NL; Ranstam J; Scherrer B; Lesaffre E; Murray G; Edler L; Hutton J; Colton T; Lachenbruch P; Verma BL
    Stat Med; 1999 Dec; 18(24):3435-51. PubMed ID: 10611617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
    Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
    Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.